Dasatinib and Quercetin Reach the Brain in Early Alzheimer's Patients
A completed Phase 1/2 pilot trial tested whether the senolytic duo D+Q penetrates the brain in early Alzheimer's disease.
20 articles
A completed Phase 1/2 pilot trial tested whether the senolytic duo D+Q penetrates the brain in early Alzheimer's disease.
Italian researchers test plant-based compounds for brain health and quality of life in aging adults with promising early results.
Probucol, a discontinued cholesterol medication, may boost brain-protective proteins in older adults at risk for dementia.
A Phase 2 trial explores whether cilostazol, a blood thinner with brain-protective effects, can slow memory loss in MCI patients.
A completed trial tests whether daily Nordic berry beverages can sharpen cognition in healthy adults over 12 weeks.
A Phase 1/2 trial tests whether dexmedetomidine can enhance the brain's glymphatic system to clear amyloid and tau during sleep.
The EPICURO trial tests MERIVA® turmeric over 6 months to see if it protects cognition in adults with metabolic syndrome.
NGP 555 targets toxic brain protein production in healthy volunteers, offering potential early intervention for Alzheimer's prevention.
A completed pilot trial tests whether 2g/day of a novel carnosine formulation can restore neuromuscular function and quality of life in MS patients.
A completed trial tests EGCG combined with diet, exercise, and cognitive training to slow decline in ApoE4 carriers with early warning signs.
A first-in-human multiple-ascending-dose trial tests Contraloid, an oral peptide designed to disassemble toxic amyloid-beta oligomers linked to Alzheimer's disease.
Contraloid acetate, an oral all-D-peptide designed to disassemble toxic amyloid-beta oligomers, completed its first-in-human safety trial in 40 healthy volunteers.
24-week trial tested fucoxanthin-rich microalgae supplement on memory, attention, and executive function in 66 healthy seniors.
Cassava Sciences' 76-week Phase 3 trial of simufilam for Alzheimer's was terminated, raising questions about the drug's future.
A Phase 2 trial investigates whether thiethylperazine, a decades-old antiemetic, can flush toxic amyloid beta from the brains of early AD patients.
A phase 2/3 trial of the BACE inhibitor atabecestat in amyloid-positive asymptomatic adults was terminated before completion, raising questions about this drug class.
A Phase II trial tests whether blocking herpes virus activity can protect against Alzheimer's disease in early cognitive decline.
A completed Phase 4 trial from India evaluates whether ALA supplementation boosts flunarizine's migraine-prevention power in adolescents.
Small pilot study tests multicomponent behavioral program to reduce cognitive decline risk in underserved rural populations.
A Canadian RCT tests whether virtual aerobic, resistance, and cognitive training can feasibly combat mild cognitive impairment at home.